WALD updates: trademark sale in Japan and credit refinancing

Rhea-AI Filing Summary

Waldencast plc reported updates via a Form 6-K, noting the sale of its rights to the “Obagi” trademark in Japan and the entry into a new credit facility. The company characterized these steps as strengthening its balance sheet.

A press release dated November 14, 2025 is attached as Exhibit 99.1 for further details. The information in this report, including the exhibit, is designated as not “filed” under Section 18 of the Exchange Act.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 or 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of: November 2025

Commission File Number: 001-40207

Waldencast plc

(Translation of Registrant’s name into English)

81 Fulham Road

London, SW3 6RD

United Kingdom

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities

On November 14, 2025, Waldencast plc provided updates with respect to the sale of its rights to the “Obagi” trademark in Japan and the entry into a new credit facility. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Report on Form 6-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

EXHIBIT INDEX

EXHIBIT NO.						DESCRIPTION
99.1						Waldencast plc press release, dated November 14, 2025

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

						Waldencast plc
						(Registrant)
Date: November 14, 2025			By:			/s/ Manuel Manfredi
						Name:			Manuel Manfredi
						Title:			Chief Financial Officer and Principal Financial Officer

3

FAQ

What did WALD announce in its Form 6-K?

Waldencast plc announced the sale of its rights to the “Obagi” trademark in Japan and the entry into a new credit facility.

When were these updates announced by WALD?

The updates were announced on November 14, 2025, with a press release attached as Exhibit 99.1.

Where can I find more details about WALD’s updates?

Further information is in the attached press release (Exhibit 99.1).

What is the stated purpose of these actions by WALD?

The company stated these actions strengthen its balance sheet position.

Is the information in this 6-K deemed filed under Section 18?

No. The report specifies the information is not deemed “filed” for purposes of Section 18 of the Exchange Act.

Who signed WALD’s 6-K and in what capacity?

Manuel Manfredi, Chief Financial Officer and Principal Financial Officer, signed the report.